LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Enrolling by invitation

Conditions studied: Psoriasis

In brief

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis

Key facts

Study ID

NCT03254667

Run by

Bausch Health Americas, Inc.

People needed

3500

Starts

2017-07-25

Expected to finish

2031-11-01

Last updated by the study team

2025-09-16

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist
• Must be at least 18 years of age or older
• Started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted.

You may not qualify if…

• The subject is unable or unwilling to provide informed consent to participate in the registry.
• The subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial).
• The subject is restarting the eligible medication less than 12 months since receiving the last dose.

Where it is running

• Registry — Bridgewater, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.